Take­da shares pos­i­tive Phase II­Ib da­ta; NIA grant for Phase II study on new oral Alzheimer's treat­ment

→ Take­da says its VAR­SI­TY, Phase II­Ib study “demon­strat­ed that the gut-se­lec­tive bi­o­log­ic vedolizum­ab (En­tyvio) was su­pe­ri­or to the an­ti-tu­mor necro­sis fac­tor-al­pha (an­ti-TN­Fα) bi­o­log­ic …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER